Clinical aspects of mCRPC management in patients treated with radium-223.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
received:
29
07
2019
accepted:
25
03
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Bone is the most common site of metastasis in metastatic castration-resistant prostate cancer (mCRPC), which is associated with pain and skeletal events. Radium-223 dichloride (Xofigo) is an alpha-emitting radioactive isotope that can specifically target bone lesions. Herein, we report the results of a retrospective analysis that documents our experience in the use of radium-223. Data from 63 patients (pts) with mCRPC who underwent radium-223 treatment from December 2015 to September 2017 were collected. Radium-223 (55 kBq/kg) was administered every 4 weeks for up to 6 cycles. The primary endpoint was OS. Radium-223 was administered as first line therapy in 11 pts, as second line in 19 pts, as third line in 16 pts and in successive lines in 17 pts; 42 pts out of 63 (67%) completed all six cycles. Within one month after the end of 6 cycles of radium-223, 15 pts out of 42 (35.7%) had achieved PR, 11 pts out of 42 (26.2%) had SD and 14 pts out of 42 (33.3%) had PD. Levels of pain decreased with progressive cycles of radium-223. After a minimum follow-up of 2 months and a maximum of 43 months, median OS was 15 months and median PFS was 8 months. The most frequent radium-223 related toxicity was low grade haematologic toxicity, predominantly G1-G2, that occurred halfway through treatment in about 75% of pts. The favourable results reported herein confirm that radium-223 can be considered well tolerated and effective in mCRPC, and is associated with significant decreases in pain.
Identifiants
pubmed: 32317750
doi: 10.1038/s41598-020-63302-2
pii: 10.1038/s41598-020-63302-2
pmc: PMC7174360
doi:
Substances chimiques
Hemoglobins
0
Radium-223
8BR2SOL3L1
Alkaline Phosphatase
EC 3.1.3.1
Prostate-Specific Antigen
EC 3.4.21.77
Radium
W90AYD6R3Q
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6681Références
Leslie, S. W., Soon-Sutton, T. L., Sajjad, H. & Siref, L. E. Prostate Cancer. [Updated 2019 Oct 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan. Available from, https://www.ncbi.nlm.nih.gov/books/NBK470550/ .
Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103, 356–387, https://doi.org/10.1016/j.ejca.2018.07.005 (2018).
doi: 10.1016/j.ejca.2018.07.005
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 66, 7–30, https://doi.org/10.3322/caac.21332 (2016).
doi: 10.3322/caac.21332
pubmed: 26742998
Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31, 578–583 (2000).
doi: 10.1053/hp.2000.6698
Logothetis, C., Morris, M. J., Den, R. & Coleman, R. E. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev 37, 189–196, https://doi.org/10.1007/s10555-017-9719-4 (2018).
doi: 10.1007/s10555-017-9719-4
pubmed: 29380085
pmcid: 5801387
Aparicio, A. M. et al. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22, 1520–1530, https://doi.org/10.1158/1078-0432.CCR-15-1259 (2016).
doi: 10.1158/1078-0432.CCR-15-1259
pubmed: 26546618
Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84–88, https://doi.org/10.1126/science.aah4307 (2017).
doi: 10.1126/science.aah4307
pubmed: 28059768
pmcid: 28059768
Logothetis, C. J. et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3, 849–861, https://doi.org/10.1158/2159-8290.CD-12-0460 (2013).
doi: 10.1158/2159-8290.CD-12-0460
pubmed: 23811619
pmcid: 3926428
Ottewell, P. D. et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer 21, 769–781, https://doi.org/10.1530/ERC-14-0199 (2014).
doi: 10.1530/ERC-14-0199
pubmed: 25052474
Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369, 213–223, https://doi.org/10.1056/NEJMoa1213755 (2013).
doi: 10.1056/NEJMoa1213755
pubmed: 23863050
Deshayes, E. et al. Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther 11, 2643–2651, https://doi.org/10.2147/DDDT.S122417 (2017).
doi: 10.2147/DDDT.S122417
pubmed: 28919714
pmcid: 5593411
Smith, M. R. et al. ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC) Ann Oncol 29, mdy424.035 (2018).
O’Sullivan, J. M. et al. The Case Against the European Medicines Agency’s Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 75, e51–e52, https://doi.org/10.1016/j.eururo.2018.11.003 (2019).
doi: 10.1016/j.eururo.2018.11.003
pubmed: 30454914
Costelloe, C. M., Chuang, H. H., Madewell, J. E. & Ueno, N. T. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1, 80–92, https://doi.org/10.7150/jca.1.80 (2010).
doi: 10.7150/jca.1.80
pubmed: 20842228
pmcid: 2938069
Cha, T. L. et al. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. J Formos Med Assoc 116, 825–836, https://doi.org/10.1016/j.jfma.2017.04.005 (2017).
doi: 10.1016/j.jfma.2017.04.005
pubmed: 29046247
Parker, C. C. et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol, https://doi.org/10.1016/j.eururo.2017.06.021 (2017).
Vogelzang, N. J. et al. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer 15, 42–52 e48, https://doi.org/10.1016/j.clgc.2016.07.027 (2017).
doi: 10.1016/j.clgc.2016.07.027
pubmed: 27613490
Boni, G. et al. 223)Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. Tumori 104, 128–136, https://doi.org/10.1177/0300891618765571 (2018).
doi: 10.1177/0300891618765571
pubmed: 29714668
Frantellizzi, V. et al. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with (223)Radium-dichloride. Ann Nucl Med 32, 142–148, https://doi.org/10.1007/s12149-017-1228-6 (2018).
doi: 10.1007/s12149-017-1228-6
pubmed: 29285670
Aapro, M., Osterborg, A., Gascon, P., Ludwig, H. & Beguin, Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23, 1954–1962, https://doi.org/10.1093/annonc/mds112 (2012).
doi: 10.1093/annonc/mds112
pubmed: 22575608
Ludwig, H., Muldur, E., Endler, G. & Hubl, W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24, 1886–1892, https://doi.org/10.1093/annonc/mdt118 (2013).
doi: 10.1093/annonc/mdt118
pubmed: 23567147
pmcid: 3690908
Sartor, O. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15, 738–746, https://doi.org/10.1016/S1470-2045(14)70183-4 (2014).
doi: 10.1016/S1470-2045(14)70183-4
pubmed: 24836273
Rosino-Sanchez, A. Preventive management of bone disease in advanced prostate cancer. Arch Esp Urol 71, 258–266 (2018).
pubmed: 29633946
Smith, M. R. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 21, 159–166 (2002).
doi: 10.1023/A:1020840311573
Smith, M. R. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 97, 789–795, https://doi.org/10.1002/cncr.11149 (2003).
doi: 10.1002/cncr.11149
pubmed: 12548577
Sartor, O. et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol 28, 1090–1097, https://doi.org/10.1093/annonc/mdx044 (2017).
doi: 10.1093/annonc/mdx044
pubmed: 28453701
pmcid: 5406754
Baldari, S. et al. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. Crit Rev Oncol Hematol 113, 43–51, https://doi.org/10.1016/j.critrevonc.2017.03.001 (2017).
doi: 10.1016/j.critrevonc.2017.03.001
pubmed: 28427521
Kelloff, G. J. et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 10, 3927–3933, https://doi.org/10.1158/1078-0432.CCR-03-0788 (2004).
doi: 10.1158/1078-0432.CCR-03-0788
pubmed: 15173102
Wong, W. W. et al. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer 15, e969–e975, https://doi.org/10.1016/j.clgc.2017.04.016 (2017).
doi: 10.1016/j.clgc.2017.04.016
pubmed: 28545997
Rathbun, J. T. & Franklin, G. E. Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort. Curr Probl Cancer 43, 205–212, https://doi.org/10.1016/j.currproblcancer.2018.05.007 (2019).
doi: 10.1016/j.currproblcancer.2018.05.007
pubmed: 29983206
Saad, F. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 17, 1306–1316, https://doi.org/10.1016/S1470-2045(16)30173-5 (2016).
doi: 10.1016/S1470-2045(16)30173-5
pubmed: 27473888
Sartor, O. et al. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist 23, 193–202, https://doi.org/10.1634/theoncologist.2017-0413 (2018).
doi: 10.1634/theoncologist.2017-0413
pubmed: 29183960
Shore, N. D. et al. eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 16, 149–154, https://doi.org/10.1016/j.clgc.2017.10.022 (2018).
doi: 10.1016/j.clgc.2017.10.022
pubmed: 29196208
De Luca, R., Costa, R. P., Tripoli, V., Murabito, A. & Cicero, G. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience. Oncology 94, 161–166, https://doi.org/10.1159/000485102 (2018).
doi: 10.1159/000485102
pubmed: 29241166
Huynh-Le, M. P., Shults, R. C., Connor, M. J. & Hattangadi-Gluth, J. A. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization. Clin Genitourin Cancer, https://doi.org/10.1016/j.clgc.2019.11.017 (2019).